●December 17, 2012: JKS News: The MHLW plan to expand the Basic Plan to Promote Cancer Control Program by setting 400 designated cancer hospitals, staffed with specialists, including psychology counselors ... Oncology drugs consulting

●November 7, 2012: Biosimilars update: The Second Subcommittee of Drugs of PAFSC, MHLW on October 31, 2012 recommended for approval the second biosimilar drug developed in Japan - biosimilar filgrastim (G-CSF), produced by technology of Gene TechnoSciences, clinically tested by Fuji Seiyaku and to marketed by Mochida Seiyaku ● Mochida Seiyaku signed an agreement with LG Biosciences for marketing in Japan of biosimilar infliximab and etanercept developed by the Korean company ... Biosimilar consulting

●October 1, 2012: MHLW announced the healthcare spending for the fiscal year FY 2011 (ending March 2012): an increase of 3.9% (compared to FY 2010) to reach total of 37.42 trillion Yen; spending for over 65 old was 702,700 Yen per capita amounting to 20.72 trillion Yen (55.4% of total spend); average per capita medical spending was 292,200 Yen. Total healthcare spend took 10.71% of national income, as the biggest allocation was for treatment of cardiovascular conditions, followed by cancer and respiratory diseases (as illustrated above)... P&R / Market access consulting

Archived headline news from other periods could be found here:

• News 2006 - 2013

The JAD News Database is currently in beta-testing and expected to be launched in 2011 for all registered users